#Bioretec #Finland #stock options #Helsinki #Medical Device

Bioretec Ltd Adjusts Stock Option Terms Following Rights Issue

Bioretec Ltd, a Finnish pioneer in medical devices, has recently made adjustments to its stock option programs. This decision comes in light of a significant rights issue that has been completed successfully, allowing the company to subscribe a total of 1,286,801,534 new shares. With the new shares now officially registered as of April 28, 2026, Bioretec is taking steps to ensure that all stakeholders, particularly option holders, are treated fairly.

Understanding the Rights Issue

The rights issue represents a strategic move by Bioretec to strengthen its capital base. By issuing new shares, the company aims to raise funds that can be reinvested into its innovative product lines and ongoing research. Such financial maneuvering is common among growing firms looking to enhance their market positioning and capacity for innovation.

Adjustments to Stock Option Terms

Under the existing terms of Bioretec's stock option programs, any issuance of new shares prior to subscription allows the company to ensure equal treatment among its shareholders and option rights holders. Specifically, the Board of Directors has the discretion to adjust either the number of shares available under the option programs or modify the subscription prices to maintain fairness among all interested parties.

To reflect the dilutive effects from the new share issue, Bioretec's Board has resolved to lower the subscription prices associated with its stock option programs. This change is essential because it means that holders of stock options are not disadvantaged by the new share issuance and continue to have an equitable stake in the company.

Subscription Price Adjustments

Here is a summary of the changes made to the subscription prices:

• - Stock Option Program 2018-1A: From €1.42 to €0.13
• - Stock Option Program 2018-1B: From €1.42 to €0.13
• - Stock Option Program 2018-1C: From €2.13 to €0.20
• - Stock Option Program 2018-1D: From €2.13 to €0.20
• - Stock Option Program 2020-1A: From €2.13 to €0.20
• - Stock Option Program 2020-1B: From €2.84 to €0.26
• - Stock Option Program 2020-1C: From €3.55 to €0.33
• - Stock Option Program 2023-1: From €2.35 to €0.22
• - Stock Option Program 2025-1: From €2.64 to €0.24

These adjustments are designed not just to retain the purchasing power of option rights holders but also to enhance investor confidence in Bioretec's governance.

About Bioretec Ltd

Founded with a vision to transform orthopedic care, Bioretec specializes in the production of biodegradable implant technologies. The company has established itself as a leader in the field, with its products being utilized in approximately 40 countries worldwide. Bioretec's commitment to innovation is evident in its RemeOs™ product line, crafted from a high-performance magnesium alloy, which promotes effective bone healing and eliminates the necessity for removal surgery.

Their product range doesn’t stop there: Bioretec's Activa line features fully bioabsorbable orthopedic implants that are already CE marked and FDA cleared for a variety of patient applications. The company emphasizes healing through absorption, paving the way for less invasive and more patient-friendly solutions in orthopedic surgery.

In conclusion, the adjustments made to Bioretec's stock option programs not only reflect a responsible approach to corporate governance but also exhibit the company's commitment to share value preservation amid growth endeavors. Stakeholders can stay informed on this evolving narrative by following Bioretec’s announcements and developments within the medical device industry.

To learn more, please visit Bioretec's official website.